Ragaglitazar

Drug Profile

Ragaglitazar

Alternative Names: DRF 2725; NN 622; NNC 610029

Latest Information Update: 07 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Reddys Research Foundation
  • Developer Novo Nordisk
  • Class Antihyperglycaemics; Antihyperlipidaemics; Oxazines; Phenylpropionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 07 Feb 2003 Discontinued - Phase-III for Type-2 diabetes mellitus in Denmark (unspecified route)
  • 26 Sep 2002 A clinical study has been added to the pharmacokinetics section
  • 29 Jul 2002 Suspended - Phase-III for Type-2 diabetes mellitus in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top